We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.40 | -0.14% | 983.40 | 983.60 | 984.00 | 991.40 | 982.40 | 989.80 | 2,111,695 | 16:35:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 32.67 | 8.59B |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2012 20:22 | UKX has bounced strongly from about these levels previously, so the next week will be interesting. | essentialinvestor | |
23/4/2012 19:44 | Plenty of downside if the FTSE reaches 5400, EI. apad | apad | |
23/4/2012 15:46 | Breached my stop loss this morning so sold at £6.05 so don't know when I'll buy back in personally. Bought some more Sainsbury's with the monies. ArtN | artnouveau | |
23/4/2012 15:44 | Don't reckon it'll see 550 again EI? apad | apad | |
23/4/2012 15:44 | Don't reckon it'll see 550 again EI? apad | apad | |
23/4/2012 14:02 | APAD, I might be tempted by some SN. on any messy general market sell off - even allowing for the MOM. | essentialinvestor | |
27/3/2012 19:50 | If it was not for that I would make a significant investment here. APAD knows the sector. | essentialinvestor | |
27/3/2012 19:42 | APAD and EssentialInvestor, the litigation for all companies historically involved in MoM could go on for years. Therefore depressing sp's. | contrarian2investor | |
20/3/2012 11:34 | Hello EI, Good question - I suspect it will be manageable in the UK, but one worries about class actions and punitive damages in the US. It is the reason I would not increase my SN. holding above its current 1.2%. Plastic acetabular cups were developed by Charnley because of problems with metal-metal interfaces and going back to them is an engineering nonsense driven by marketing and patents. apad | apad | |
20/3/2012 10:53 | APAD, if you are aroung do you have any view on the potential for future claims from metal on metal implants?. | essentialinvestor | |
01/3/2012 14:00 | "New CEO is cutting costs and moving manufacturing to cheaper countries" I usually think this is good news, but surely an effect on revenue. For example, if they were to shut down plants with no definitive process mapped operation offshore then I fail to see how this helps their P&L. | nscap | |
24/2/2012 13:18 | EI Good points, and I own AMS but think them very highly priced at the moment. But, hey, did you see how my SN. buy moved the market:-) apad | apad | |
24/2/2012 09:49 | They tend to buy in the private rather than the listed sector. Between news flow for now so not suprised at a minor retrace given the large % jump on previous results. | essentialinvestor | |
24/2/2012 09:39 | Morning EI, Increased my holding this morning. Reasons to be cheerful: Increasing wound care market (it might purchase AMS (but I hope it doesn't)) Sound artificial joint business Sound finances New CEO is cutting costs and moving manufacturing to cheaper countries Cheap pound Yield is 6.4 times monies on deposit :-) I reckon this is a rerating story for the Tintins in 2012. apad ps look at CPI go! Can't time 'em all. | apad | |
08/2/2012 13:24 | Broker Daniel Stewart has chosen two companies from each of its primary coverage sectors - financials, healthcare, leisure, materials, metals & mining, oil & gas and software - as its top picks for 2012. In financials, the broker prefers Close Brothers (LON:CBG) and Standard Chartered (LON:STAN). While the healthcare picks were Abcam (LON:ABC) and Smith & Nephew (LON:SN.). | lucky_punter | |
06/2/2012 16:07 | Lots of people appear to be considering selling at these levels, not sure if it is an outright sell - however on 14x 2013 numbers (if met) it looks a full price, just in my view. | essentialinvestor | |
02/2/2012 15:52 | I was going to sell then thought why the company is run well and always the old bid speculation in for nothing so still holding | nw99 | |
02/2/2012 12:39 | this is so undervalued | inv | |
02/2/2012 12:20 | Thought of selling but still here! | philo124 | |
02/2/2012 11:15 | Not even one post on results day. | essentialinvestor | |
05/1/2012 06:22 | Smith & Nephew to spin off its biologics arm By Helia Ebrahimi8:10PM GMT 04 Jan 2012 | l2user | |
14/11/2011 11:03 | Upgraded by Exane apparently and some good press at the weekend. ArtN | artnouveau | |
14/11/2011 10:40 | Have to see wether there is follow through when US opens. | philo124 | |
14/11/2011 10:03 | $4bn turnover and profits varying between $400-600mn. 'Tis a sitting duck and about ruffle a few feathers IMHO. ArtN | artnouveau |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions